Основная статистика
| LEI | 549300B5CQV1OOXFLU71 |
| CIK | 1532346 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Atreca, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| April 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Atreca, Inc. |
|
| April 11, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38935 ATRECA, INC. (Exact name of registrant as specified in its charter |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38935 ATRECA, INC. Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 900 East Hamilton |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| February 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| February 6, 2024 |
Exhibit 10.2 December 31, 2023 Stephen Gould Re: Separation and Consulting Agreement Dear Stephen: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Atreca, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date shall be today, December 31, 2023 (the “Separat |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 6, 2024 |
Exhibit 10.1 January 31, 2024 Tito Serafini Re: Separation and Consulting Agreement Dear Tito: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Atreca, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. SEPARATION. Your employment termination date shall be today, January 31, 2024 (the “Separati |
|
| January 10, 2024 |
EX-99.1 2 tm242424d3ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Atreca, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. January 10, 2024 BAKER BROS. ADVISORS LP By: B |
|
| January 10, 2024 |
BCEL / Atreca, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Atreca, Inc. |
|
| January 5, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and Courtney J. Phillips (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive previo |
|
| December 26, 2023 |
Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT by and between Atreca, Inc. and Immunome, Inc. Dated as of December 22, 2023 Table of Contents Page ARTICLE 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Interpretation 12 ARTICLE 2 SALE AND PURCHASE 12 2.1 Sale and Purchase; Transferred Assets; Assumed Liabilities 12 2.2 Closing Consideration 14 2.3 Closing 15 2.4 Third Party Consents 15 2. |
|
| December 26, 2023 |
Exhibit 10.1 Confidential FORM of Support AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of December 22, 2023, by and among Atreca, Inc., a Delaware corporation (the “Company”), Immunome, Inc., a Delaware corporation (“Purchaser”), and the Person set forth on Schedule A hereto ( “Stockholder”). WHEREAS, as of the date hereof, Stockholder is a Beneficial Owner of, and has sole or sh |
|
| December 26, 2023 |
Exhibit 99.1 Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome CAMPBELL, Calif., December 26, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced t |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and Courtney J. Phillips (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive previo |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and John A. Orwin (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive previously en |
|
| December 26, 2023 |
Exhibit 10.1 Confidential FORM of Support AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of December 22, 2023, by and among Atreca, Inc., a Delaware corporation (the “Company”), Immunome, Inc., a Delaware corporation (“Purchaser”), and the Person set forth on Schedule A hereto ( “Stockholder”). WHEREAS, as of the date hereof, Stockholder is a Beneficial Owner of, and has sole or sh |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and Tito A. Serafini, Ph.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive pre |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and John A. Orwin (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive previously en |
|
| December 26, 2023 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of December 19, 2023, (the “Effective Date”) by and between Atreca, Inc. (the “Company”), and Tito A. Serafini, Ph.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Company and Executive pre |
|
| December 26, 2023 |
Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT by and between Atreca, Inc. and Immunome, Inc. Dated as of December 22, 2023 Table of Contents Page ARTICLE 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Interpretation 12 ARTICLE 2 SALE AND PURCHASE 12 2.1 Sale and Purchase; Transferred Assets; Assumed Liabilities 12 2.2 Closing Consideration 14 2.3 Closing 15 2.4 Third Party Consents 15 2. |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 26, 2023 |
Exhibit 99.1 Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome CAMPBELL, Calif., December 26, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced t |
|
| November 14, 2023 |
EXHIBIT 99.1 Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the ac |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 21, 2023 |
AGREEMENT FOR MODIFICATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES Exhibit 10.1 AGREEMENT FOR MODIFICATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Modification of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of September 20, 2023 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ATRECA, INC., a Delaware corporation (“Tenan |
|
| September 21, 2023 |
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross Exhibit 99.1 Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross SAN CARLOS, Calif., September 21, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today a |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 21, 2023 |
Exhibit 10.2 September 18, 2023 Herb Cross Re: Separation and Consulting Agreement Dear Herb: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Atreca, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date shall be Friday, September 22, 2023 (the “Separation Date” |
|
| September 14, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 18, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-273314 Prospectus $10,599,000 Class A Common Stock We have entered into a Common Stock Sales Agreement dated July 18, 2023, or the sales agreement, with Cowen and Company, LLC, or TD Cowen, relating to the sale of shares of our Class A common stock offered by this prospectus. In accordance with the terms of the sales agreeme |
|
| August 16, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 16, 2023 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 16, 2023 Registration No. 333-273314 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporatio |
|
| August 16, 2023 |
ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 VIA EDGAR August 16, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Atreca, Inc. Registration Statement on Form S-3 File No. 333-273314 Acceleration Request Requested Date: August 17, 2023 Requested Time: 5:00 P.M |
|
| August 10, 2023 |
EXHIBIT 99.1 Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnolo |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRE |
|
| July 27, 2023 |
ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 VIA EDGAR July 27, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Atreca, Inc. Registration Statement on Form S-3 File No. 333-273314 Filed July 18, 2023 Dear Mr. McNamara: We hereby withdraw our prior acceleratio |
|
| July 26, 2023 |
ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 ATRECA, INC. 835 Industrial Road, Suite 400, San Carlos, CA 94070 (650) 595-2595 VIA EDGAR July 26, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Atreca, Inc. Registration Statement on Form S-3 File No. 333-273314 Filed July 18, 2023 Acceleration Request Requested Date: July 27, 2023 Requeste |
|
| July 18, 2023 |
Sales Agreement, by and between the Company and Cowen and Company, LLC, dated July 18, 2023. Exhibit 1.2 Atreca, inc. $91,521,058 class a common stock SALES AGREEMENT July 18, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Atreca, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| July 18, 2023 |
Exhibit 4.6 ATRECA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 |
|
| July 18, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 ATRECA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and |
|
| July 18, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 ATRECA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and |
|
| July 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Atreca, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forw |
|
| July 18, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 ATRECA, INC. AND , AS WARRANT AGENT FORM OF CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT THIS CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [ |
|
| July 18, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 18, 2023 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 18, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATR |
|
| May 10, 2023 |
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 27, 2023 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 27, 2023; TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRECA, INC. (Exact name o |
|
| March 29, 2023 |
EXHIBIT 99.1 Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 prog |
|
| March 29, 2023 |
Form of Stock Option Grant Notice and Option Agreement for Atreca, Inc. 2023 Inducement Plan EX-10.24 5 bcel-20221231xex10d24.htm EX-10.24 Exhibit 10.24 For U.S. Participants ATRECA, INC. 2023 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE Atreca, Inc. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions |
|
| March 29, 2023 |
Exhibit 10.22 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Philippe Bishop This Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Philippe Bishop (the “Executive”) (collectively, the “Parties”), is effective as of January 9, 2023. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with cert |
|
| March 29, 2023 |
June 15, 2022, by and between the Registrant and Stephen Gould Exhibit 10.21 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for STEPHEN GOULD This Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Stephen Gould (the “Executive”) (collectively, the “Parties”), is effective as of June 15, 2022. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain co |
|
| March 29, 2023 |
Form of RSU Grant Notice and Award Agreement for Atreca, Inc. 2023 Inducement Plan Exhibit 10.25 For U.S. Participants ATRECA, INC. 2023 INDUCEMENT PLAN RESTRICTED STOCK UNIT GRANT NOTICE Atreca, Inc. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby awards to Participant, as an inducement material to Participant’s entering into employment with the Company, a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted |
|
| March 29, 2023 |
Exhibit 99.3 ATRECA, INC. STOCK OPTION GRANT NOTICE (INDUCEMENT GRANT OUTSIDE OF 2019 EQUITY INCENTIVE PLAN) Atreca, Inc. (the “Company”) hereby grants to the individual below (“Optionholder”)an option (the “Option”) to purchase the number of shares of the Company’s Common Stock set forth below. This Option is granted outside of the Company’s 2019 Equity Incentive Plan (the “Plan”), and is subject |
|
| March 29, 2023 |
Exhibit 99.4 ATRECA, INC. INDUCEMENT GRANT OUTSIDE OF 2019 EQUITY INCENTIVE PLAN OPTION AGREEMENT (NONSTATUTORY STOCK OPTION) Pursuant to your Grant Notice and this option agreement (the “Option Agreement”), Atreca, Inc. (the “Company”) has granted you an Option to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Gra |
|
| March 29, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2023 As filed with the U.S. Securities and Exchange Commission on March 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRECA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3723255 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employ |
|
| March 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Atreca, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Proposed Maximum Amount to be Registered (1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock, p |
|
| March 29, 2023 |
Exhibit 10.23 ATRECA, INC. 2023 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: FEBRUARY 9, 2023 1.GENERAL. (a)Eligible Award Recipients. The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related gu |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 10, 2022 |
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update EXHIBIT 99.1 Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) - SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the ac |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2022 |
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financi |
|
| August 8, 2022 |
Option and License Agreement, dated April 4, 2022, by and between the Registrant and Zymeworks Inc. Exhibit 10.1 ? CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? Confidential Execution Version OPTION AND LICENSE AGREEMENT Between ZYMEWORKS INC. and ATRECA, INC. April 4, 2022 ? ? TABLE OF CONTENTS ? ? ? ? ? ? Page ARTICLE 1 DEFINITIONS AND INTERPRETATIONS 1 A |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 1, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2022 |
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 28, 2022 |
DEFA14A 1 tm223615d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 5, 2022 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 24, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Atreca, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock, par value $0.0001 per sha |
|
| March 24, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 24, 2022 As filed with the U.S. Securities and Exchange Commission on March 24, 2022 Registration No. 333-[?] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRECA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3723255 (State or other jurisdiction of Incorporation or organization) (I.R.S. Emp |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 3, 2022 |
Exhibit 10.17 ? CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? AMENDMENT NO. 2 TO EXCLUSIVE (EQUITY) AGREEMENT This AMENDMENT NO. 2 TO EXCLUSIVE (EQUITY) AGREEMENT (?Amendment?) is effective as of July 2, 2020 (?Amendment Effective Date?), by and between The B |
|
| March 3, 2022 |
EXHIBIT 99.1 Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity observed in multiple tumor types and significantly associated with ATRC-101 target expression; ta |
|
| March 3, 2022 |
Exhibit 10.27 ? CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? Execution Version ? License Agreement [***] ? This License Agreement (this ?Agreement?) is entered into as of the date of last signature (the ?Effective Date?) by the Bill & Melinda Gates Medical R |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRECA, INC. (Exact name |
|
| February 14, 2022 |
BCEL / Atreca, Inc. Class A / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2022 |
BCEL / Atreca, Inc. Class A / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Atreca, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Class A Common Stock, $0.0001 par value per share, of Atreca, Inc., |
|
| February 14, 2022 |
BCEL / Atreca, Inc. Class A / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2022 |
BCEL / Atreca, Inc. Class A / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 10, 2021 |
BCEL / Atreca, Inc. Class A / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Atreca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04965G109 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 15, 2021 |
BCEL / Atreca, Inc. Class A / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 04965G109 (CUSIP Number) November 1, 20211 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 2, 2021 |
Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financia |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 21, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique |
|
| October 21, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 Atreca, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 11, 2021 |
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financi |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 11, 2021 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| July 29, 2021 |
EXHIBIT 99.1 Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed mechanism of action (MOA) as elucidated in preclinical |
|
| July 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 29, 2021 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 20, 2021 |
Letter from OUM & Co. LLP to the Securities and Exchange Commission Exhibit 16.1 July 15, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Ladies and Gentlemen: We have read Atreca, Inc.?s statements included under Item 4.01 of its Form 8-K dated July 15, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K. Very truly yours, /s/ OUM & Co. LLP |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 13, 2021 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R |
|
| May 13, 2021 |
Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments SAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2021 |
Exhibit 10.1 March 26, 2021 Norman Greenberg 12625 High Meadow Road North Potomac, MD 20878 ? Re:Transition Separation and Consulting Agreement Dear Norm: This letter sets forth the substance of the transition separation and consulting agreement (the ?Agreement?) that Atreca, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1.SEPARATION DATE. As you know, you have volu |
|
| April 28, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????? ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRECA, |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 26, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRECA, INC. (Exact name |
|
| February 26, 2021 |
February 26, 2021 (File No. 333-253577) As filed with the U.S. Securities and Exchange Commission on February 26, 2021 Registration No. 333-[?] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRECA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3723255 (State or other jurisdiction of Incorporation or organization) (I.R.S. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 25, 2021 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 25, 2021 |
Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Atreca Inc., which ma |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Atreca, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Atreca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2020 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 12, 2020 |
Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced |
|
| November 12, 2020 |
Exhibit 10.7 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for NORMAN GREENBERG This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Norman Greenberg (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 (the “Effective Date”). WHEREAS, Executive and the Company previously entere |
|
| November 12, 2020 |
Exhibit 10.5 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for TITO SERAFINI This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Tito Serafini (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 (the “Effective Date”). WHEREAS, Executive and the Company previously entered into |
|
| November 12, 2020 |
Exhibit 10.3 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for JOHN ORWIN This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and John Orwin (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 ( (the “Effective Date”). WHEREAS, Executive and the Company previously entered into tha |
|
| November 12, 2020 |
Exhibit 10.8 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for COURTNEY PHILLIPS This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Courtney Phillips (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 (the “Effective Date”). WHEREAS, Executive and the Company previously ente |
|
| November 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 |
|
| November 12, 2020 |
Exhibit 10.4 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for HERBERT CROSS This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Herbert Cross (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 (the “Effective Date”). WHEREAS, Executive and the Company previously entered into |
|
| November 12, 2020 |
Exhibit 10.6 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for LISA LYNN DECKER This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Lisa Lynn Decker (the “Executive”) (collectively, the “Parties”), is effective as of November 11, 2020 (the “Effective Date”). WHEREAS, Executive and the Company previously entere |
|
| August 12, 2020 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2020 |
Prospectus Supplement (To prospectus dated July 10, 2020) Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 12, 2020 |
Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announce |
|
| August 12, 2020 |
Exhibit 10.2 ? ATRECA, INC. $100,000,000 ? CLASS A COMMON STOCK ? SALES AGREEMENT ? August 12, 2020 ? Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 ? Ladies and Gentlemen: ? Atreca, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1.Issuance and Sale of Shares. The Company agrees that, from t |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 12, 2020 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| August 12, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ATRECA, INC. IF PUBLICLY DISCLOSED. ? Execution Version ? COLLABORATION AND LICENSE AGREEMENT ? by and between ? XENCOR, INC. ? and ? ATRECA, INC. ? Dated as of July 2, 2020 ? ? ? ? ? TABLE OF CONTENTS ? ? ? ? Page ? ? ARTIC |
|
| August 12, 2020 |
9,466,951 Shares Class A Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) File No. |
|
| August 12, 2020 |
Prospectus Supplement (To prospectus dated July 10, 2020) Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 17, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 16, 2020 |
Underwriting Agreement, dated as of July 15, 2020 Exhibit 1.1 EXECUTION VERSION 7,812,500 Shares Atreca, Inc. Common Stock UNDERWRITING AGREEMENT July 15, 2020 Cowen AND Company, LLC Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o Stifel, N |
|
| July 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2020 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 15, 2020 |
Subject to Completion, Dated July 15, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 8, 2020 |
ATRECA, INC. 450 East Jamie Court South San Francisco, California 94080 (650) 595-2595 July 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Atreca, Inc. Registration Statement on Form S-3 Filed July 2, 2020 File No. 333-239654 Ladies and Gentlemen: In accordance with Rule 461 un |
|
| July 8, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 8, 2020 |
ATRECA, INC. 450 East Jamie Court South San Francisco, California 94080 (650) 595-2595 July 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Atreca, Inc. Registration Statement on Form S-3 Filed July 2, 2020 File No. 333-239652 Ladies and Gentlemen: In accordance with Rule 461 un |
|
| July 2, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 ATRECA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and |
|
| July 2, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the U. |
|
| July 2, 2020 |
Exhibit 4.6 ATRECA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 D |
|
| July 2, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 ATRECA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and |
|
| July 2, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on July 2, 2020 Registration No. |
|
| July 2, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 ATRECA, INC. AND , AS WARRANT AGENT FORM OF CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT DATED AS OF ATRECA, INC. FORM OF CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT THIS CLASS A [CLASS B] COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ATRECA, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] orga |
|
| June 16, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 14, 2020 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R |
|
| May 14, 2020 |
Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced |
|
| May 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATREC |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 29, 2020 |
definitive proxy statement on Schedule 14A, filed on April 29, 2020; QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 ATRECA, INC. (Exact name of |
|
| March 11, 2020 |
Atreca, Inc. Non-Employee Director Compensation Policy. Exhibit 10.11 ATRECA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Approved by the Board of Directors: May 23, 2019 Effective Date: June 19, 2019 Amended January 27, 2020 Each member of the Board of Directors (the “Board”) of Atreca, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non |
|
| March 11, 2020 |
Atreca Reports Fourth Quarter and Full Year 2019 Financial Results EXHIBIT 99.1 Atreca Reports Fourth Quarter and Full Year 2019 Financial Results SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results |
|
| March 11, 2020 |
Exhibit 10.10 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of March 11, 2020, by and between Atreca, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the |
|
| March 11, 2020 |
Description of Registrant’s Securities Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Registra |
|
| March 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k031120.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 11, 2020 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation |
|
| March 11, 2020 |
Atreca, Inc. Performance Bonus Plan Exhibit 10.12 ATRECA, INC. PERFORMANCE BONUS PLAN Approved by the Compensation Committee of the Board of Directors: March 10, 2020 PURPOSE The Atreca, Inc. Performance Bonus Plan (the “Plan”) is designed to allow all eligible Atreca, Inc. (“Atreca” or “Company”) employees eligibility for a discretionary bonus based on the Company’s and the individual employee’s performance. The primary purpose of |
|
| March 11, 2020 |
March 11, 2020 (File No. 333-237090) As filed with the U.S. Securities and Exchange Commission on March 11, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRECA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3723255 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employ |
|
| February 14, 2020 |
04965G109 / Atreca Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2020 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Atreca, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2020 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general p |
|
| February 14, 2020 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the Class A Common Stock of Atreca, Inc., par value $0.0001, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, |
|
| February 14, 2020 |
04965G109 / Atreca Inc / Baker Brothers Advisors LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
04965G109 / Atreca Inc / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Atreca, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 04965G109 (CUSIP Number) February 13, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2020 |
04965G109 / Atreca Inc / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Atreca, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 12, 2020 |
04965G109 / Atreca Inc / Bill & Melinda Gates Foundation Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 27, 2020 |
BCEL / Atreca, Inc. Class A / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Atreca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04965G109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2019 Atreca, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 12, 2019 |
BCEL / Atreca, Inc. Class A 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38935 A |
|
| November 12, 2019 |
Letter Agreement, dated as of November 7, 2019, by and between the Registrant and Susan Berland. Exhibit 10.3 November 7, 2019 Susan Berland 321 N. San Mateo Drive #101 San Mateo, CA 94401 Amendment of Stock Options Dear Susan: I am pleased to advise you that on October 7, 2019, the Compensation Committee (the “Committee”) of the Board of Directors of Atreca, Inc. (the “Company”) approved an amendment to your stock options to purchase 22,493 shares, 2,333 shares, 21,929 shares, 18,418 shares, |
|
| November 12, 2019 |
Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) - Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the third quarter ended September 30, 2019, a |
|
| August 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2019 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 13, 2019 |
Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments EXHIBIT 99.1 Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif.—(BUSINESS WIRE) — August 13, 2019 — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, an |
|
| August 13, 2019 |
Executive Employment Agreement, dated June 10, 2019, between the Registrant and Courtney Phillips Exhibit 10.7 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Courtney Phillips This Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Courtney Phillips (the “Executive”) (collectively, the “Parties”), is effective as of June 10, 2019. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with cer |
|
| August 13, 2019 |
Letter Agreement, dated May 28, 2019, between the Registrant and Lisa Decker. Exhibit 10.6 May 28, 2019 Lisa Decker 942 Baileyana Road Hillsborough, CA 94010 Re: Employment Terms Dear Lisa: Atreca, Inc. (“Atreca” or the “Company”) is pleased to offer you the exempt position of Chief Business Officer on the following terms. You will be responsible for the duties typical of your position and as assigned by your supervisor, and you will report to John Orwin, President & Chief |
|
| August 13, 2019 |
BCEL / Atreca, Inc. Class A 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38853 ATRECA |
|
| July 23, 2019 |
Lease Agreement dated July 17, 2019, between the Registrant and ARE-EAST JAMIE COURT, LLC. EXHIBIT 10.18 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 17 day of July, 2019, between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and ATRECA, INC., a Delaware corporation (“Tenant”). Building: 450 East Jamie Court, South San Francisco, California Premises: A Building consisting of approximately 74,788 rentable square feet, as determined by L |
|
| July 23, 2019 |
Lease Agreement dated July 17, 2019, between the Registrant and ARE-SAN FRANCISCO NO. 63, LLC. EXHIBIT 10.19 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 17 day of July, 2019, between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ATRECA, INC., a Delaware corporation (“Tenant”). Building: That certain to-be-constructed 6-story building to be known as 835 Industrial Road, San Carlos, California Premises: A portion of the Building con |
|
| July 23, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 10, 2019 |
BCEL / Atreca, Inc. Class A / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atreca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04965G109 (CUSIP Number) June 28, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| July 1, 2019 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the Class A common stock of Atreca, Inc., par value $0.0001, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, |
|
| July 1, 2019 |
BCEL / Atreca, Inc. Class A / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atreca, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 04965G109 (CUSIP Number) June 24, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| June 28, 2019 |
BCEL / Atreca, Inc. Class A / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Atreca, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 04965G109 (CUSIP Number) June 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| June 26, 2019 |
Form of Class A Common Stock Certificate of the Registrant. Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# . CLASS A COMMON STOCK PAR VALUE $0.0001 CLASS A COMMON STOCK Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * Certificate Number ZQ00000000 AT |
|
| June 26, 2019 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ATRECA, INC. (A DELAWARE CORPORATION) June 24, 2019 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 2 Section 6. Special Meetings 6 Section 7. Notice of |
|
| June 26, 2019 |
Form of Class B Common Stock Certificate of the Registrant. Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# . CLASS B COMMON STOCK PAR VALUE $0.0001 CLASS B COMMON STOCK Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * Certificate Number ZQ00000000 AT |
|
| June 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2019 Atreca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38935 27-3723255 (State or Other Jurisdiction (IRS Employer of Incorporation) (Commissio |
|
| June 26, 2019 |
Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATRECA, INC. The undersigned, John A. Orwin, hereby certifies that: ONE: The original name of this corporation is Atreca, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 11, 2010. TWO: He is the duly elected and acting President an |
|
| June 25, 2019 |
BCEL / Atreca, Inc. Class A / Redmile Group, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ATRECA, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 04965G 109 (CUSIP Number) June 24, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| June 25, 2019 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Atreca, Inc., which m |
|
| June 21, 2019 |
2019 Employee Stock Purchase Plan. Exhibit 99.3 ATRECA, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. (b) The Company, by me |
|
| June 21, 2019 |
June 21, 2019 (File No. 333-232278) As filed with the U.S. Securities and Exchange Commission on June 21, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRECA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3723255 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employe |
|
| June 21, 2019 |
2019 Equity Incentive Plan, and forms of agreements thereunder. Exhibit 99.2 ATRECA, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 2, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2019 IPO DATE/EFFECTIVE DATE: June 19, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Atreca, Inc. 2010 Equity Incentive Plan (the ?Prior Plan?). From and after 12:01 a.m. Pacific time on t |
|
| June 20, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| June 17, 2019 |
BCEL / Atreca, Inc. Class A CORRESP - - ATRECA, INC. 500 Saginaw Drive Redwood City, CA 94063 VIA EDGAR June 17, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Franklin Wyman Kevin Vaughn Julia Griffith Dietrich King RE: Atreca, Inc. Registration Statement on Form S-1, As Amended (File No. 333-231770) Request for Acceleration of Effective Date Ladies and Gentl |
|
| June 17, 2019 |
BCEL / Atreca, Inc. Class A CORRESP - - Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Evercore Group L. |
|
| June 10, 2019 |
Atreca, Inc. 2010 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.2 ATRECA, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 2, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2019 IPO DATE/EFFECTIVE DATE: [DATE] 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Atreca, Inc. 2010 Equity Incentive Plan (the ?Prior Plan?). From and after 12:01 a.m. Pacific time on the Effe |
|
| June 10, 2019 |
Form of Underwriting Agreement. Exhibit 1.1 [?] Shares Atreca, Inc. Common Stock UNDERWRITING AGREEMENT June [?], 2019 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o Stifel, Nicolaus & Company, Inco |
|
| June 10, 2019 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATRECA, INC. The undersigned, John A. Orwin, hereby certifies that: ONE: The original name of this corporation is Atreca, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 11, 2010. TWO: He is the duly elected and acting President an |
|
| June 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Atreca, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State of Incorporation or Organization) 27-3723255 (I.R.S. Employer Identification No.) 500 Saginaw Drive Redwood City, |
|
| June 10, 2019 |
Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT , MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ATRECA, INC. IF PUBLICLY DISCLOSED. Execution Version NOMINATING AGREEMENT THIS NOMINATING AGREEMENT (this ?Agreement?), dated as of September 5, 2018, by and among Atreca, Inc., a Delaware corporation (the ?Company?), Bak |
|
| June 10, 2019 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATRECA, INC. Atreca, Inc., a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the ?DGCL?), hereby certifies that: ONE: The date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 11, 2010 |
|
| June 10, 2019 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT , MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ATRECA, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE (EQUITY) AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (?Stanford?), an institution of higher education having powers under th |
|
| June 10, 2019 |
Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT , MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ATRECA, INC. IF PUBLICLY DISCLOSED. August 21, 2015 Atreca, Inc. 75 Shoreway Rd, Suite C San Carlos, CA 94047-2727 Re: Program Related Investment by the Bill & Melinda Gates Foundation in Atreca, Inc. Ladies and Gentleman: |
|
| June 10, 2019 |
Exhibit 10.17 AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENT This AMENDMENT TO THE EXCLUSIVE (EQUITY) AGREEMENT (the ?Amendment?) is effective as of May 24, 2018 (the ?Amendment Effective Date?) by and between ATRECA, INC., a Delaware corporation, located at 500 Saginaw Drive, Redwood City, California 94063-4750 (?Atreca?), and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, an institut |
|
| June 10, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on June 10, 2019 Registration No. |
|
| June 10, 2019 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ATRECA, INC. (A DELAWARE CORPORATION) , 2019 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 2 Section 6. Special Meetings 6 Section 7. Notice of Meeting |
|
| June 10, 2019 |
Atreca, Inc. 2019 Employee Stock Purchase Plan. Exhibit 10.3 ATRECA, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. (b) The Company, by me |
|
| June 3, 2019 |
BCEL / Atreca, Inc. Class A CORRESP - - *FOIA Confidential Treatment Request* Confidential Treatment Requested by Atreca, Inc. |
|
| May 24, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on May 24, 2019 Registration No. |
|
| May 24, 2019 |
Exhibit 10.10 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Guy Cavet This Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and Guy Cavet (the ?Executive?) (collectively, the ?Parties?), is effective as of April 30, 2016. WHEREAS, the Company desires for Executive to continue to provide services to the Company, and wishes to provide Executive with certa |
|
| May 24, 2019 |
Exhibit 10.6 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for John Orwin This Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and John Orwin (the ?Executive?) (collectively, the ?Parties?), is effective as of March 21, 2018 (?Effective Date?). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive wi |
|
| May 24, 2019 |
Exhibit 10.4 ATRECA, INC. INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (the ?Agreement?) is made and entered into as of , between Atreca, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. Highly competent persons have become more reluctant to serve corporations as directors or officers or in other capacities unless they are provided with adequate protection through insu |
|
| May 24, 2019 |
BCEL / Atreca, Inc. Class A CORRESP - - Michael E. Tenta T: +1 650 843 5636 [email protected] VIA EDGAR AND FEDEX May 24, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Franklin Wyman Kevin Vaughn Julia Griffith Dietrich King RE: Atreca, Inc. Draft Registration Statement on Form S-1 Submitted April 24, 2019 CIK No. 0001532346 Ladies and Gentlemen: On behalf of |
|
| May 24, 2019 |
Exhibit 10.11 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Susan Berland This Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and Susan Berland (the ?Executive?) (collectively, the ?Parties?), is effective as of April 19 , 2016. WHEREAS, the Company desires for Executive to continue to provide services to the Company, and wishes to provide Executive w |
|
| May 24, 2019 |
Exhibit 10.7 ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for Tito Serafini This Amended and Restated Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and Tito Serafini (the ?Executive?) (collectively, the ?Parties?), is effective as of date all parties have signed this Agreement (the ?Effective Date?). WHEREAS, Executive and the Compa |
|
| May 24, 2019 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATRECA, INC. Atreca, Inc., a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the ?DGCL?), hereby certifies that: ONE: The date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware |
|
| May 24, 2019 |
Lease, dated as of June 6, 2014, by and between the Registrant and HCP LS Redwood City, LLC. Exhibit 10.5 LEASE BRITANNIA SEAPORT CENTER HCP LS REDWOOD CITY, LLC, a Delaware limited liability company as Landlord, and ATRECA, INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 4 2. LEASE TERM; OPTION TERM 5 3. BASE RENT 7 4. ADDITIONAL RENT 7 5. USE OF PREMISES 13 6. SERVICES AND UTILITIES 18 7. REPAIRS 19 8. ADDITIONS AND ALTERA |
|
| May 24, 2019 |
Sublease, dated as of March 22, 2016, by and between the Registrant and CardioDx, Inc. Exhibit 10.12 SUBLEASE (500 SAGINAW DRIVE, REDWOOD CITY, CALIFORNIA) THIS SUBLEASE (this ?Sublease?) is entered into as of March 22, 2016 (the ?Effective Date?), by and between CARDIODX, INC., a Delaware corporation (?Sublandlord?), and ATRECA, INC., a Delaware corporation (?Subtenant?) (Sublandlord and Subtenant, each, a ?Party?, and collectively, the ?Parties?). RECITALS This SUBLEASE is made wi |
|
| May 24, 2019 |
Exhibit 10.8 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Herb Cross This Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and Herb Cross (the ?Executive?) (collectively, the ?Parties?), is effective as of February 1, 2019. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compen |
|
| May 24, 2019 |
Exhibit 10.9 ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Norman Greenberg This Executive Employment Agreement (the ?Agreement?), made between Atreca, Inc. (the ?Company?) and Norman Greenberg (the ?Executive?) (collectively, the ?Parties?), is effective as of March 25, 2016. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with cert |
